Oliver Sexton

Oliver Sexton

Oliver invests from UKI2S, an early stage seed/series A fund that backs companies developing complex science and engineering led solutions to global challenges. Specialising in life science investments Oliver joined UKI2S in 2014. He has therapeutic, med tech, agritech and industrial biotech companies in the portfolio and sits on the board of Ikarovec, a gene therapy company and Gyreox, a macrocycle company as well as observer positions at the cell therapy company Cytox.

Prior to joining UKI2S Oliver managed commercialisation of bioengineering and medical technologies at Imperial Innovations and worked at Ark Therapeutics as well as managing a team of biotech buy-side analysts.

Position Investment Director

Telephone 0121 710 1990

“Turning world-leading research into profitable companies is no simple matter, but we are now at a point where many of those technologies are suitable for broad commercial application. The UK Innovation & Science Seed Fund is providing not just capital, but the expertise and the networks to maximize the chances of success in existing markets and in the new markets that synthetic biology enables.”

 

 

Oliver Sexton

Associated Companies

Relevant News

University of Birmingham spin-out secures £2m to develop medical diagnostic technology

Image Left to right: Junior Research Scientist Jake Cotterill, Research Scientist Lorea Orueta, Linear Diagnostics Ltd Chief…

read more

Astellas Announces Acquisition of Quethera

Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program…

read more

Scientists scramble to stop bananas being killed off

Banana plantations in Australia, south-east Asia, Africa and the Middle East have been ravaged by…

read more

Nemesis Bioscience Closes Funding Round And Begins Preclinical Programmes

8th May 2017 Nemesis Bioscience today announced the successful completion of its latest funding round,…

read more

Cytox Announces Participation In Insight Alzheimer’s Study

13 October 2015 Participation will aid comparison of SNP genotyping with biomarker status Cytox Ltd,…

read more

Case Studies

Case Study - Synthace

London-based Synthace provides next-generation software and processes to exponentially improve productivity in bioscience, enabling people…

read more

Case Study - ZuvaSyntha Ltd

Summary: ZuvaSyntha is developing proprietary renewable manufacturing routes to industrial chemicals from low cost feedstocks…

read more

Blog

Today’s Academic Projects Are Becoming Tomorrow’s Billion Pound Companies

  When we talk about the tech revolution that is currently sweeping the industrialised world,…

read more

Other Team Members

Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now

×